Loading
scrollUp

Information showcased is only for the professional doctors / practising doctors

Why MOLFLUTM

MOLFLUTM contains Molnupiravir 200 mg capsules. In a first-of-its-kind collaboration in the Indian pharmaceutical industry, a Dr. Reddy's-led consortium of pharma companies collaborated to jointly sponsor, supervise, and monitor the phase III clinical trial in India and presented its findings to the Subject Expert Committee (SEC).1

MOLFLUTM is available in strip packaging at a very reasonable price of Rs. 35/- per capsule, ensuring good quality as it is manufactured in a WHO-GMP certified plant.

Why Molnupiravir?

Molnupiravir is an investigational oral antiviral agent that is currently being studied in clinical trials for the treatment of adults with COVID-19 with SpO2 >93% and those who have high risk of progression of the disease, including hospitalization or death.*

Molnupiravir is still undergoing clinical trials. In the MOVe-OUT Phase 3 clinical trial, the incidence of most frequent drug-related adverse events ≥1% were diarrhea (1.7%), nausea (1.4%), and dizziness (1%).2

Where to use?

• In the treatment of adults with COVID-19 with SpO2 >93% and who have high   risk of progression of the disease,   including hospitalization or death.*

-->

Knowledge Hub

   

 * MOLFLUTM Prescribing Information. † Data on file

References:

    1. Dr. Reddy's gets DCGI nod for Molnupiravir, to launch soon. Available from: https://www.thehindubusinessline.com/companies/dr-reddys-gets-dcgi-nod-formolnupiravir-to-launch-soon/article38056291.ece. Accessed on: 20th January, 2022.

    2. Bernal JA, da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Eng J Med. 2021;NEJMoa2116044.

    3. US FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir [Internet] US FDA [Updated 2021 Dec 23; Cited 2022 Jan 04].Available from: https://www.fda.gov/media/155054/download. Accessed on: 5th January, 2022.

    4. UK EMC. Lagevrio 200 mg hard capsules. Summary of Product Characteristics (SmPC) [Internet] UK EMC [Updated 2021 Nov 05; Cited 2022 Jan 04].Available from: https://www.medicines.org.uk/emc/product/13044/smpc#gref.

    5. Dr Reddys Laboratories; Press release dated 28th Dec 2021. [Internet] Dr Reddys Laboratories Ltd. Hyderabad [Cited 2022 Jan 04]. Available from:https://www.drreddys.com/media/1057220/press-release-dr-reddys-molnupiravir.pdf.

    6. Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740–746.

GGI-CO-A1-OR-300035676-300035676-WM-B22-137